
LivaNova price target raised after strong Q2 revenue and EPS beat, signaling growth in medical tech.
LivaNova's stock price target was raised to $85 following a strong Q2 performance with record revenue of $390.6 million, up 9.8%, and adjusted EPS of $1.26, beating estimates by 16.67%. The growth was driven by its Cardiopulmonary and Epilepsy segmen...

